Brief: Xeris Biopharma Enters Into Exclusive License Agreement For Xeriject

Xeris Biopharma Holdings

10/01/2024 13:14

Jan 10 (Reuters) - Xeris Biopharma Holdings Inc
 XERS.O :
    * XERIS BIOPHARMA ENTERS INTO AN EXCLUSIVE WORLDWIDE LICENSE
AGREEMENT FOR XERIJECT® FORMULATION OF TEPROTUMUMAB
    * : UNDER DEAL, XERIS HAS POTENTIAL TO RECEIVE $75 MILLION
IN
DEVELOPMENT AND REGULATORY MILESTONES, PLUS SALES-BASED
MILESTONES
    * XERIS HAS POTENTIAL TO RECEIVE $75 MILLION IN MILESTONES
AND
ROYALTIES
    * : UNDER DEAL, CO TO RECEIVE ESCALATING SINGLE-DIGIT
ROYALTIES
BASED ON FUTURE SALES OF TEPEZZA USING XERIJECT TECHNOLOGY

Source text for Eikon:  ID:nBw3NDZPra 
Further company coverage:  XERS.O 

 ((Reuters.Briefs@thomsonreuters.com;))